BACKGROUND: Data regarding the association of antibody levels elicited after immunization with the BNT162b2 mRNA Covid-19 vaccine with epidemiological and clinical parameters are limited. METHODS: We prospectively measured the total (TAbs-RBD) and the neutralizing antibodies (NAbs-RBD) against the receptor binding domain (RBD) of SARS-CoV-2 spike protein in a cohort of 268 Healthcare workers before immunization, 20 days after the 1(st) dose and 30 days after the 2(nd) dose of the BNT162b2 vaccine. A statistical analysis for possible association of antibodies’ levels with epidemiological and clinical parameters was performed. RESULTS: The mean age (±SD) of the participants was 45.45 years (± 11.93) (range: 24-70 years) and 211 (79.9%) were females. Statistically significant differences were detected regarding both TAbs-RBD and NAbs-RBD between the first and second doses of the vaccine (P<0.001). The median (IQR) percentage (%) of NAbs-RBD after the 1(st) dose was 51.07% (31.60%) and after the 2(nd) dose 95.31% (3.70%) (P<0.001).The correlation between the TAbs-RBD and NAbs-RBD was after the 1(st) dose, Spearman’s, rho: 0.861 (P<0.001) and after the 2(nd) dose rho: 0.989 (P<0.001). Twenty days after the 1(st) dose, 56/264 (21.2%) of the participants did not have detectable NAbs-RBD, while one month after the 2(nd) dose all of them had detectable NAbs-RBD. After the 2(nd) vaccine dose, a statistically significant negative association of TAbs-RBD was detected for age (P<0.001), smoking (P=0.011), and immunosuppressive medications (P<0.001), while a positive association was detected for BMI (P=0.004) and systemic adverse events after immunization (P=0.001). CONCLUSION: A significant correlation of TAbs-RBD and NAbs-RBD was detected after both vaccine doses. Older age, smoking, and immunosuppressive medications negatively affected the final antibody level after SARS-CoV-2 immunization. Our findings emphasize the significance of the 2(nd) vaccine dose especially in the older age groups.
Association of total and neutralizing SARS-CoV-2 spike -Receptor Binding Domain antibodies with epidemiological and clinical characteristics after immunization with the 1st and 2nd doses of the BNT162b2 vaccine